Galecto has been granted a patent for a compound and method to treat disorders related to galectin-3 binding in mammals, including inflammation, cancer, heart disease, and more. The formula I compound effectively targets and treats a variety of conditions in humans. GlobalData’s report on Galecto gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Galecto Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Galecto, NSAID cancer drugs was a key innovation area identified from patents. Galecto's grant share as of February 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11919921B2) discloses a method for treating disorders related to the binding of galectin-3 to a ligand in mammals. The disorders include a wide range such as inflammation, fibrosis, cancer, autoimmune diseases, heart disease, metabolic disorders, and more. The method involves administering a therapeutically effective amount of a compound with a specific formula or its pharmaceutically acceptable salt.

Specific disorders mentioned in the claims include pulmonary fibrosis, liver fibrosis, kidney fibrosis, various types of cancers, autoimmune diseases, heart failure, and non-alcoholic steatohepatitis. The method also covers specific types of cancers like carcinomas, sarcomas, leukemias, lymphomas, and metastasizing cancers. Additionally, it includes conditions like interstitial lung fibrosis, liver cirrhosis, cardiovascular disorders, and cardiac fibrosis. The method specifies the administration of the compound in amorphous form and in pharmaceutical compositions like tablets or capsules, with the mammal being a human.

To know more about GlobalData’s detailed insights on Galecto, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies